{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:07:18Z","timestamp":1793657238205,"version":"4.5.1"},"reference-count":159,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Patients with inborn errors of immunity (IEI) have been transplanted for more than 50 years. Many long-term survivors have ongoing medical issues showing the need for further improvements in how hematopoietic stem cell transplantation (HSCT) is performed if patients in the future are to have a normal quality of life. Precise genetic diagnosis enables early treatment before recurrent infection, autoimmunity and organ impairment occur. Newborn screening for severe combined immunodeficiency (SCID) is established in many countries. For newly described disorders the decision to transplant is not straight-forward. Specific biologic therapies are effective for some diseases and can be used as a bridge to HSCT to improve outcome. Developments in reduced toxicity conditioning and methods of T-cell depletion for mismatched donors have made transplant an option for all eligible patients. Further refinements in conditioning plus precise graft composition and additional cellular therapy are emerging as techniques to personalize the approach to HSCT for each patient<\/jats:p>","DOI":"10.3389\/fimmu.2023.1162605","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:40:10Z","timestamp":1680655210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Personalized hematopoietic stem cell transplantation for inborn errors of immunity"],"prefix":"10.3389","volume":"14","author":[{"given":"Mary","family":"Slatter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Han","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(68)92673-1","article-title":"Immunological reconstitution of sex-linked lymphopenic immunological deficiency","volume":"2","author":"Gatti","year":"1968","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-662-30498-3_8","article-title":"Barrier nursing of an infant in a laminar cross-flow bench","volume":"38","author":"de Koning","year":"1970","journal-title":"Maandschr Kindergeneeskd"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(68)92672-X","article-title":"Bone-marrow transplantation in a patient with the wiskott-Aldrich syndrome","volume":"2","author":"Bach","year":"1968","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","article-title":"Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01278-6","article-title":"Retrospective, landmark analysis of long-term adult morbidity following allogeneic HSCT for inborn errors of immunity in infancy and childhood","volume":"42","author":"Day","year":"2022","journal-title":"J Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01286-6","article-title":"Quality of life and social and psychological outcomes in adulthood following allogeneic HSCT in childhood for inborn errors of immunity","volume":"42","author":"Nicholson","year":"2022","journal-title":"J Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90477-0","article-title":"Bone-marrow transplantation for immunodeficiencies and osteopetrosis: European survey, 1968-1985","volume":"2","author":"Fischer","year":"1986","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.4.1149.1149","article-title":"Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European group for BMT and the European group for immunodeficiency","volume":"83","author":"Fischer","year":"1994","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92348-L","article-title":"European Experience of bone-marrow transplantation for severe combined immunodeficiency","volume":"336","author":"Fischer","year":"1990","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12513-5","article-title":"Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99","volume":"361","author":"Antoine","year":"2003","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jaci.2010.06.015","article-title":"Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better","volume":"126","author":"Gennery","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.jaci.2021.10.017","article-title":"Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort","volume":"149","author":"Lankester","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.10.022","article-title":"The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 definitions","volume":"151","author":"Dvorak","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","article-title":"Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification","volume":"40","author":"Bousfiha","year":"2020","journal-title":"J Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15061","DOI":"10.1038\/nrdp.2015.61","article-title":"Severe combined immunodeficiencies and related disorders","volume":"1","author":"Fischer","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.9132","article-title":"Newborn screening for severe combined immunodeficiency in 11 screening programs in the united states","volume":"312","author":"Kwan","year":"2014","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01448","article-title":"First year of Israeli newborn screening for severe combined immunodeficiency-clinical achievements and insights","volume":"8","author":"Rechavi","year":"2017","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10875-016-0347-5","article-title":"Newborn screening for severe primary immunodeficiency diseases in Sweden-a 2-year pilot TREC and KREC screening study","volume":"37","author":"Barbaro","year":"2017","journal-title":"J Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.05.007","article-title":"An evaluation of the TREC assay with regard to the integration of SCID screening into the Dutch newborn screening program","volume":"180","author":"Blom","year":"2017","journal-title":"Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.13659","article-title":"Newborn screening for severe combined immunodeficiency: Evaluation of a commercial T-cell receptor excision circle-based method in Victorian dried blood spots","volume":"54","author":"Richards","year":"2018","journal-title":"J Paediatr Child Health"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.03.012","article-title":"Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results","volume":"202","author":"Thomas","year":"2019","journal-title":"Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02406","article-title":"First universal newborn screening program for severe combined immunodeficiency in europe. two-years' experience in Catalonia (Spain)","volume":"10","author":"Argudo-Ramirez","year":"2019","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s10875-020-00865-9","article-title":"Infections in infants with SCID: Isolation, infection screening, and prophylaxis in PIDTC centers","volume":"41","author":"Dorsey","year":"2021","journal-title":"J Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1993.4.4-521","article-title":"Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. amendment to clinical research project, project 90-C-195, January 10, 1992","volume":"4","author":"Blaese","year":"1993","journal-title":"Hum Gene Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608653","article-title":"Immune reconstitution after gene therapy approaches in patients with X-linked severe combined immunodeficiency disease","volume":"11","author":"Blanco","year":"2020","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.gendis.2019.07.007","article-title":"Gene therapy and genome editing for primary immunodeficiency diseases","volume":"7","author":"Zhang","year":"2020","journal-title":"Genes Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010260","article-title":"Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency","volume":"138","author":"Reinhardt","year":"2021","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41591-021-01641-x","article-title":"Long-term safety and efficacy of lentiviral hematopoietic stem\/progenitor cell gene therapy for wiskott-Aldrich syndrome","volume":"28","author":"Magnani","year":"2022","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.106","article-title":"Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer","volume":"25","author":"Pike-Overzet","year":"2011","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.08.014","article-title":"Biosafety studies of a clinically applicable lentiviral vector for the gene therapy of Artemis-SCID","volume":"15","author":"Charrier","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2021.03.001","article-title":"Targeted genome editing for the correction or alleviation of primary immunodeficiencies","volume":"182","author":"Sipe","year":"2021","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840702","article-title":"SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery","volume":"132","author":"Haddad","year":"2018","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0540-9","article-title":"Long-term health outcome and quality of life post-HSCT for IL7Ralpha-, Artemis-, RAG1- and RAG2-deficient severe combined immunodeficiency: A single center report","volume":"38","author":"Abd Hamid","year":"2018","journal-title":"J Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-748616","article-title":"Long-term outcome of hematopoietic stem cell transplantation for IL2RG\/JAK3 SCID: A cohort report","volume":"129","author":"Abd Hamid","year":"2017","journal-title":"Blood."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177923","article-title":"Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency","volume":"113","author":"Neven","year":"2009","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-476432","article-title":"SCID patients with ARTEMIS vs RAG deficiencies following HCT: Increased risk of late toxicity in ARTEMIS-deficient SCID","volume":"123","author":"Schuetz","year":"2014","journal-title":"Blood."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01403-5","article-title":"Impact of genetic diagnosis on the outcome of hematopoietic stem cell transplant in primary immunodeficiency disorders","volume":"43","author":"Forlanini","year":"2023","journal-title":"J Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jaci.2009.10.038","article-title":"Large Deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome","volume":"124","author":"Engelhardt","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905506","article-title":"Combined immunodeficiency associated with DOCK8 mutations","volume":"361","author":"Zhang","year":"2009","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-0126-0","article-title":"DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients","volume":"35","author":"Aydin","year":"2015","journal-title":"J Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.10.035","article-title":"Hematopoietic stem cell transplantation as treatment for patients with DOCK8 deficiency","volume":"7","author":"Aydin","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013496","article-title":"Abatacept is useful in autoimmune cytopenia with immunopathologic manifestations caused by CTLA-4 defects","volume":"139","author":"Dhunputh","year":"2022","journal-title":"Blood."},{"key":"B49","doi-asserted-by":"publisher","first-page":"108779","DOI":"10.1016\/j.clim.2021.108779","article-title":"Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency","volume":"229","author":"Lanz","year":"2021","journal-title":"Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jaci.2016.01.045","article-title":"Hematopoietic stem cell transplantation for CTLA4 deficiency","volume":"138","author":"Slatter","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-602763","article-title":"Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations","volume":"125","author":"Milner","year":"2015","journal-title":"Blood."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201906-1204LE","article-title":"Successful treatment of interstitial lung disease in STAT3 gain-of-Function using JAK inhibitors","volume":"202","author":"Silva-Carmona","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2022.09.002","article-title":"Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome","author":"Leiding","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749721","article-title":"Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant","volume":"129","author":"Hiwarkar","year":"2017","journal-title":"Blood."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.03.040","article-title":"Multicenter phase 1\/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation","volume":"20","author":"Ip","year":"2018","journal-title":"Cytotherapy"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jaci.2015.12.1311","article-title":"Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes","volume":"137","author":"Naik","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.10.003","article-title":"American Society of transplantation and cellular therapy series, 2: Management and prevention of aspergillosis in hematopoietic cell transplantation recipients","volume":"27","author":"Dadwal","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1996562","article-title":"Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections","volume":"23","author":"Panagopoulou","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myab025","article-title":"Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"59","author":"Bogler","year":"2021","journal-title":"Med Mycol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00239","article-title":"Hematopoietic cell transplantation in patients with primary immune regulatory disorders (PIRD): A primary immune deficiency treatment consortium (PIDTC) survey","volume":"11","author":"Chan","year":"2020","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692219","article-title":"The use of biologic modifiers as a bridge to hematopoietic cell transplantation in primary immune regulatory disorders","volume":"12","author":"Arnold","year":"2021","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00435","article-title":"Haematopoietic stem cell transplantation for primary haemophagocytic lymphohistiocytosis","volume":"7","author":"Lehmberg","year":"2019","journal-title":"Front Pediatr"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1182\/blood-2019-124477","article-title":"Alemtuzumab as first line treatment in children with familial lymphohistiocytosis","volume":"134","author":"Moshous","year":"2019","journal-title":"Blood."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24188","article-title":"Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab","volume":"60","author":"Marsh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/art.41103","article-title":"Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis","volume":"72","author":"Eloseily","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13054-020-02878-7","article-title":"IL6-r blocking with tocilizumab in critically ill patients with hemophagocytic syndrome","volume":"24","author":"Dufranc","year":"2020","journal-title":"Crit Care"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood."},{"key":"B73","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: A large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \"activated PI3Kdelta syndrome\"-targeted therapy with the PI3Kdelta inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0960","article-title":"Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen","volume":"105","author":"Rao","year":"2005","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-828277","article-title":"Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies","volume":"132","author":"Allen","year":"2018","journal-title":"Blood."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701217","article-title":"Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells","volume":"21","author":"Olivieri","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703098","article-title":"Acute left ventricular failure following melphalan and fludarabine conditioning","volume":"28","author":"Ritchie","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"B79","doi-asserted-by":"publisher","first-page":"20406207211013985","DOI":"10.1177\/20406207211013985","article-title":"Treosulfan-based conditioning for inborn errors of immunity","volume":"12","author":"Slatter","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0850-2","article-title":"Treosulfan\/fludarabine: a new conditioning regimen in allogeneic transplantation","author":"Casper","year":"2004","journal-title":"Ann Hematol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704784","article-title":"Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications","volume":"35","author":"Beelen","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705553","article-title":"Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with shwachman-diamond syndrome","volume":"39","author":"Sauer","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07064.x","article-title":"Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities","volume":"142","author":"Greystoke","year":"2008","journal-title":"Br J Haematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312082","article-title":"Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United kingdom experience","volume":"117","author":"Slatter","year":"2011","journal-title":"Blood."},{"key":"B85","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/bmt.2012.188","article-title":"Long-term follow-up of children conditioned with treosulfan: German and Austrian experience","volume":"48","author":"Beier","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094730","article-title":"Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis","volume":"99","author":"Lehmberg","year":"2014","journal-title":"Haematologica"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.bbmt.2014.08.020","article-title":"Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial","volume":"20","author":"Burroughs","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B88","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/pbc.25267","article-title":"Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning","volume":"62","author":"Dinur-Schejter","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.171","article-title":"Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases","volume":"50","author":"Slatter","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-704015","article-title":"Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience","volume":"128","author":"Morillo-Gutierrez","year":"2016","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.11.009","article-title":"Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience","volume":"24","author":"Slatter","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14960","article-title":"High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study","volume":"179","author":"van der Stoep","year":"2017","journal-title":"Br J Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.09.018","article-title":"Impact of treosulfan exposure on early and long-term clinical outcomes in pediatric allogeneic hematopoietic stem cell transplantation recipients: A prospective multicenter study","volume":"28","author":"van der Stoep","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1715","article-title":"Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: Results from a prospective trial","volume":"108","author":"Chiesa","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.988","article-title":"Pharmacokinetics and pharmacodynamics of treosulfan in patients with thalassemia major undergoing allogeneic hematopoietic stem cell transplantation","volume":"104","author":"Mohanan","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0866-9","article-title":"Anti-mullerian hormone and inhibin b after stem cell transplant in childhood: A comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens","volume":"55","author":"Leiper","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.05.005","article-title":"Gonadal function after busulfan compared with treosulfan in children and adolescents undergoing allogeneic hematopoietic stem cell transplant","volume":"25","author":"Faraci","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1989.01670160072011","article-title":"Observations and proposed mechanism of N,N',N''-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation","volume":"125","author":"Horn","year":"1989","journal-title":"Arch Dermatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03914-2","article-title":"Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma","volume":"84","author":"Kondo","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study","volume":"383","author":"Gungor","year":"2014","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.03.008","article-title":"Low exposure busulfan conditioning to achieve sufficient multilineage chimerism in patients with severe combined immunodeficiency","volume":"25","author":"Dvorak","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B102","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jtct.2022.01.013","article-title":"Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation","volume":"28","author":"Bognar","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.135","article-title":"Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation","volume":"10","author":"Ansari","year":"2009","journal-title":"Pharmacogenomics"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.15.98","article-title":"Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Choi","year":"2015","journal-title":"Pharmacogenomics"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3778","article-title":"Glutathione s-transferase M1 polymorphism: A risk factor for hepatic venoocclusive disease in bone marrow transplantation","volume":"104","author":"Srivastava","year":"2004","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.06.021","article-title":"Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients","volume":"23","author":"Ivaturi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0715-9","article-title":"Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation","volume":"58","author":"Langenhorst","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"key":"B110","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jaci.2017.02.036","article-title":"Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders","volume":"141","author":"Slack","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-022-01284-6","article-title":"Worked to the bone: antibody-based conditioning as the future of transplant biology","volume":"15","author":"Griffin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2013.201","article-title":"Haematopoietic stem cell niches: New insights inspire new questions","volume":"32","author":"Ugarte","year":"2013","journal-title":"EMBO J"},{"key":"B113","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/j.bbmt.2018.12.172","article-title":"Toxicity-free hematopoietic stem cell engraftment achieved with anti-CD117 monoclonal antibody conditioning","volume":"25","author":"Agarwal","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60945-4","article-title":"Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: A phase 1\/2 study","volume":"374","author":"Straathof","year":"2009","journal-title":"Lancet."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1730.x","article-title":"Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis","volume":"93","author":"Bergamaschi","year":"1996","journal-title":"Br J Haematol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jaci.2020.04.033","article-title":"Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency","volume":"147","author":"Castiello","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.03.003","article-title":"Myeloid conditioning with c-kit-Targeted CAR-T cells enables donor stem cell engraftment","volume":"26","author":"Arai","year":"2018","journal-title":"Mol Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.04.007","article-title":"Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward","volume":"30","author":"Ali","year":"2016","journal-title":"Blood Rev"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-284349","article-title":"Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases","volume":"117","author":"Schulz","year":"2011","journal-title":"Blood."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-659672","article-title":"Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT","volume":"127","author":"Marsh","year":"2016","journal-title":"Blood."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01460-1","article-title":"A prospective pilot study of a novel alemtuzumab target concentration intervention strategy","volume":"56","author":"Arnold","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00315","article-title":"Differential elimination of anti-thymocyte globulin of fresenius and genzyme impacts T-cell reconstitution after hematopoietic stem cell transplantation","volume":"10","author":"Oostenbrink","year":"2019","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00375-6","article-title":"Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): A single-arm, phase 2 clinical trial","volume":"9","author":"Admiraal","year":"2022","journal-title":"Lancet Haematol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: Unique contributions of gammadelta T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1086\/322843","article-title":"Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role","volume":"184","author":"Lafarge","year":"2001","journal-title":"J Infect Dis"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-599423","article-title":"Gammadelta T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-alphabeta+\/CD19+ lymphocytes","volume":"125","author":"Airoldi","year":"2015","journal-title":"Blood."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563817","article-title":"HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and b cells in children with nonmalignant disorders","volume":"124","author":"Bertaina","year":"2014","journal-title":"Blood."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jaci.2017.07.008","article-title":"T-Cell receptor alphabeta(+) and CD19(+) cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency","volume":"141","author":"Shah","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.008","article-title":"Single-center experience of unrelated and haploidentical stem cell transplantation with TCRalphabeta and CD19 depletion in children with primary immunodeficiency syndromes","volume":"21","author":"Balashov","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001757","article-title":"Mismatched related vs matched unrelated donors in TCRalphabeta\/CD19-depleted HSCT for primary immunodeficiencies","volume":"134","author":"Laberko","year":"2019","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00648-x","article-title":"Use of TCR alpha(+)beta(+)\/CD19(+)-depleted haploidentical hematopoietic stem cell transplant is a viable option in patients with primary immune deficiency without matched sibling donor","volume":"39","author":"Brettig","year":"2019","journal-title":"J Clin Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.08.006","article-title":"Selective depletion of alphabeta T cells and b cells for human leukocyte antigen-haploidentical hematopoietic stem cell transplantation. a three-year follow-up of procedure efficiency","volume":"22","author":"Li Pira","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and b-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005628","article-title":"TCRalphabeta\/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders","volume":"6","author":"Merli","year":"2022","journal-title":"Blood Adv"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01152-2","article-title":"Improved survival and graft function in ex vivo T-cell depleted haploidentical hematopoietic cell transplantation for primary immunodeficiency","volume":"56","author":"Lum","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01239-z","article-title":"TCRalphabeta-depleted haploidentical grafts are a safe alternative to HLA-matched unrelated donor stem cell transplants for infants with severe combined immunodeficiency","volume":"42","author":"Tsilifis","year":"2022","journal-title":"J Clin Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004072","article-title":"T-Replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity","volume":"6","author":"Lum","year":"2022","journal-title":"Blood Adv"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0318-y","article-title":"Outcome of children with primary immunodeficiencies receiving alpha\/beta T-cell depleted HLA-haplo-HSCT followed by infusion of lymphocytes transduced with the inducible caspase 9 (iC9) suicide gene","volume":"53","author":"Algeri","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B141","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.bbmt.2018.12.080","article-title":"Administration of BPX-501 cells follwoing AB T- and b-cell depleted HLA-haploidentical HSCT (haplo-HSCT) in children with malignant or non-malignant disorders","volume":"25","author":"Merli","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B142","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1182\/blood-2018-99-119792","article-title":"Administration of rimiducid follwoing haploidentical BPX-501 cells in children with malignant or non-malignant disorders who develop graft-versus-host-disease","author":"Elfeky","year":"2018","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jaci.2014.08.019","article-title":"CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: A preliminary study","volume":"135","author":"Touzot","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"10.1111\/tid.12823","DOI":"10.1111\/tid.12823","article-title":"Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion","volume":"20","author":"Triplett","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0035-y","article-title":"Low-dose donor memory T-cell infusion after TCR alpha\/beta depleted unrelated and haploidentical transplantation: Results of a pilot trial","volume":"53","author":"Maschan","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0750-7","article-title":"Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution","volume":"55","author":"Mamcarz","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1.O076","DOI":"10.1038\/s41409-022-01815-2","article-title":"Pilot study on memory T-cell addback after TCRAB\/CD19 depleted haploidentical hematopoietic cell transplantation in children with non-SCID inborn errors of immunity","volume":"57","author":"Lum","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bolanos-Meade","year":"2012","journal-title":"Blood."},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26783","article-title":"Reduced-toxicity alternate-donor stem cell transplantation with posttransplant cyclophosphamide for primary immunodeficiency disorders","volume":"65","author":"Rastogi","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00600-z","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide for primary immune deficiency disorders in children: Challenges and outcome from a tertiary care center in south India","volume":"39","author":"Uppuluri","year":"2019","journal-title":"J Clin Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.03.009","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children","volume":"25","author":"Neven","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.215285","article-title":"T-Cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors","volume":"104","author":"Kurzay","year":"2019","journal-title":"Haematologica"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.03.018","article-title":"HLA-haploidentical hematopoietic cell transplantation for treatment of nonmalignant diseases using nonmyeloablative conditioning and post-transplant cyclophosphamide","volume":"26","author":"Mallhi","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00856-w","article-title":"Hematopoietic stem cell transplantation in children with inborn errors of immunity: a multi-center experience in Colombia","volume":"40","author":"Olaya","year":"2020","journal-title":"J Clin Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00898-0","article-title":"Reduced intensity bone marrow transplantation with post-transplant cyclophosphamide for pediatric inherited immune deficiencies and bone marrow failure syndromes","volume":"41","author":"Klein","year":"2021","journal-title":"J Clin Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.04.024","article-title":"Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years","volume":"132","author":"Kwan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/ijns7040072","article-title":"Establishing newborn screening for SCID in the USA; experience in California","volume":"7","author":"Puck","year":"2021","journal-title":"Int J Neonatal Screen"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01934-9","article-title":"Ensuring a future for gene therapy for rare diseases","volume":"28","author":"Aiuti","year":"2022","journal-title":"Nat Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.32032","article-title":"Gene-targeted therapies: Towards equitable development, diagnosis, and access","volume":"193","author":"Gaviglio","year":"2023","journal-title":"Am J Med Genet C Semin Med Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1162605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:40:14Z","timestamp":1680655214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1162605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":159,"alternative-id":["10.3389\/fimmu.2023.1162605"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1162605","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"article-number":"1162605"}}